FDA reviews Ziihera combinations for HER2-positive gastroesophageal cancer, showing potential benefit as a first-line ...
FDA accepts Zanidatamab combo sBLA for HER2+ gastroesophageal cancer, showing improved outcomes in HERIZON-GEA-01 trial with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results